Stock Chart

NVO

$39.05 -0.96%
Score: 51.2 HOLD
LEAPs: SELL $43
i
LEAPs Option Signal

Type: SELL growth_1yr
Strike: $43
Premium: $4.30
Expiry: Sep 17, 2027
Target: $37
Score: -100

LEAPs are long-term options (1+ year) with less time decay.
Pro
Screener
Vol: 0.82x (vs SPY: 1.0x | vs QQQ: 1.0x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 23, 2026
Bear Pennant weak / forming — below our quality gate quality 49/100
A Bear Pennant is taking shape but hasn't passed our quality gate (60/100), so no projected path or levels are shown — only the forming rails on the chart below.
Historically breaks down 70% of the time (n=1,730). Measured-move targets failed our backtest — none shown.
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About NVO - Novo-Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Key Statistics

Market Cap $174B
P/E Ratio 9.55
Dividend Yield 0.05%

This NVO stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track NVO's price movements with trendlines, gamma walls, and key support/resistance levels.